Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Sparteine is a quinolizidine alkaloid derived from Scotch broom (Cytisus scoparius) that acts as a sodium channel blocker. Despite historical use as an antiarrhythmic agent and labor inducer, sparteine lacks clinical validation from modern randomized controlled trials.
Origin & History
Sparteine is a naturally occurring tetracyclic bis-quinolizidine alkaloid (C₁₅H₂₆N₂) primarily extracted from plants in the Fabaceae family, particularly Lupinus mutabilis (where it is the predominant alkaloid) and Cytisus scoparius (scotch broom). It is biosynthesized in plant chloroplasts via lysine decarboxylation to cadaverine, followed by enzymatic coupling involving Δ¹-piperideine and 17-oxosparteine synthase.
Research Narrative (Provisional)
No human randomized controlled trials, meta-analyses, or large-scale clinical studies were identified in PubMed or other databases for therapeutic applications of sparteine. The compound is absent from the Vaughan Williams classification and has no FDA-approved clinical uses, with toxicity concerns (cardiotoxic and neurotoxic at high doses) limiting human trials.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Sparteine is a pure alkaloid compound (C15H26N2), not a food or nutritional ingredient, therefore it has no macronutrient, micronutrient, vitamin, mineral, or fiber content. Molecular weight: 234.38 g/mol. It is a bicyclic quinolizidine alkaloid (tetracyclic structure with four nitrogen-containing rings) found naturally in Scotch broom (Cytisus scoparius) at concentrations of approximately 0.3-1.5% dry weight, lupine seeds (Lupinus spp.) at 0.02-0.5% dry weight, and lesser amounts in other Fabaceae species. As a bioactive compound, its pharmacologically relevant concentration range in isolated form is typically studied at 10-100 mg doses in historical clinical contexts. Bioavailability when ingested orally is reported as moderate, with hepatic first-pass metabolism via CYP2D6 enzyme pathway being the primary metabolic route; CYP2D6 poor metabolizers show significantly elevated plasma concentrations. Sparteine sulfate (the pharmaceutical salt form) has a reported oral bioavailability of approximately 40-60%. It is lipid-soluble (logP approximately 2.6), enabling CNS penetration. No caloric value, protein, fat, or carbohydrate content is applicable. It is not classified as a nutrient by any regulatory body.
Reported Mechanism (Provisional)
Sparteine functions as a class 1a antiarrhythmic agent by blocking voltage-gated sodium channels in cardiac tissue, specifically targeting the Nav1.5 channels. The compound also exhibits oxytocic properties by stimulating uterine smooth muscle contractions through calcium channel modulation. Additionally, sparteine demonstrates weak anticholinergic activity at nicotinic acetylcholine receptors.
Clinical Narrative (Provisional)
No randomized controlled trials have validated sparteine's therapeutic efficacy for any medical condition. Historical case reports from the early-to-mid 20th century documented its use as an antiarrhythmic agent, but these lacked placebo controls and standardized dosing protocols. Traditional obstetric applications for labor induction were based on observational data rather than controlled clinical studies. Modern cardiology and obstetrics have replaced sparteine with safer, evidence-based alternatives due to its narrow therapeutic window and potential toxicity.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.